证券代码：002030 证券简称：达安基因 公告编号：2025-022 一、续聘会计师事务所事项的情况说明 致同会计师事务所（特殊普通合伙）（以下简称"致同"）具备从事证券、 期货相关业务资格，具有丰富的上市公司审计工作经验。在过去的 2024 年审计 服务中，致同严格遵循相关法律、法规和政策，遵照独立、客观、公正的执业准 则，按进度完成了公司各项审计工作，其出具的各项报告能够客观、公正、公允 地反映公司财务情况和经营结果，较好地履行了审计机构职责，从专业角度维护 了公司及股东的合法权益。 为保持审计工作的连续性和稳定性，董事会审计委员会提议续聘致同会计师 事务所（特殊普通合伙）为公司 2025 年度的财务审计机构和内部控制审计机构， 2025 年度审计费用拟授权公司管理层与致同根据市场行情商定。 二、续聘会计师事务所的基本信息 （一）机构信息 1.基本信息 广州达安基因股份有限公司 关于续聘致同会计师事务所（特殊普通合伙）为公司 2025 年度财务审计机构和内控审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-023 广州达安基因股份有限公司 关于召开 2025 年第一次临时股东会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司(以下简称"公司")第八届董事会 2025 年第二 次临时会议决定于 2025 年 5 月 15 日（星期四）召开公司 2025 年第一次临时股 东会，现将本次股东会的有关事项通知如下： 一、召开股东会的基本情况 1、股东会届次：2025 年第一次临时股东会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开时间： （1）现场会议召开时间：2025 年 5 月 15 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 15 日上午 9：15-9：25，9：30-11：30 和下午 13：00-15：00；通 过深圳证券交易所互联网投票系统投票的时间为 2025 年 5 月 15 日上 ...

证券代码：002030 证券简称：达安基因 公告编号：2025-020 广州达安基因股份有限公司 1、会议以 4 票赞成，0 票反对，0 票弃权审议通过了公司《2025 年第一季 度报告》。 根据《证券法》第 82 条的要求，监事会对广州达安基因股份有限公司 2025 年第一季度报告进行了审核，并提出书面审核意见如下： 经审核，监事会认为董事会编制和审核广州达安基因股份有限公司 2025 年 第一季度报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 公司《 2025 年 第 一 季 度 报 告 》 全 文 详 见 公 司 指 定 信 息 披 露 网 站 （http://www.cninfo.com.cn），并刊登于 2025 年 4 月 30 日《证券时报》、《上 海证券报》（公告编号：2025-021）。 2、会议以 4 票赞成，0 票反对，0 票弃权审议通过了公司《关于续聘致同会 计师事务所（特殊普通合伙）为公司 2025 年度财务审计机构和内控审计机构的 预案》。 第八届监事会 2025 年第一次临时会议决议 ...

广州达安基因股份有限公司 第八届董事会 2025 年第二次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司(以下简称"公司"、"达安基因")于 2025 年 4 月 23 日以邮件的形式发出会议通知，于 2025 年 4 月 29 日（星期二）上午 10∶ 00 在广州市高新区科学城香山路 19 号公司一楼会议室以现场和通讯表决相结合 的方式召开第八届董事会 2025 年第二次临时会议。本次会议由董事长薛哲强先 生主持，公司应到董事 9 名，实到董事 9 名。公司监事、公司高管列席会议。会 议的召开符合《公司法》、《公司章程》以及有关法律、法规的规定。本次会议以 投票表决的方式，审议并通过了以下决议： 一、会议以 9 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《2025 年第一季度报告》。 经审核，董事会认为报告内容真实、准确、完整地反映了公司的实际情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 公 司 《 2025 年 第 一 季 度 报 告 》 全 文 详 见 公 司 指 定 信 息 披 露 网 ...

Financial Performance - The company's revenue for Q1 2025 was ¥169,136,638.98, a decrease of 14.71% compared to ¥198,307,676.45 in the same period last year[5] - Net profit attributable to shareholders was ¥52,924,282.00, a significant increase of 114.57% from a loss of ¥363,290,638.81 in the previous year[5] - Basic and diluted earnings per share were both ¥0.04, representing a 115.38% increase from -¥0.26 in the same period last year[5] - Operating profit turned positive at ¥93.18 million compared to a loss of ¥433.31 million in the previous period[28] - Net profit for the period was ¥51.26 million, a significant recovery from a net loss of ¥361.14 million in the prior year[28] - The company reported a total comprehensive income of ¥51.22 million, recovering from a loss of ¥360.92 million in the previous year[29] Cash Flow - The net cash flow from operating activities improved by 59.14%, reaching -¥36,693,867.25 compared to -¥89,798,669.28 in the previous year[5] - The net cash flow from operating activities was CNY -36,693,867.25, a 59.14% improvement compared to CNY -89,798,669.28 in the previous year, mainly due to reduced salary and bonus payments[13] - Cash flow from operating activities showed a net outflow of ¥36.69 million, an improvement from a net outflow of ¥89.80 million in the previous period[31] - The net cash flow from investing activities was CNY 43,714,694.14, a 142.95% increase from CNY -101,776,732.65 in the previous year, attributed to the maturity of large deposits and recovery of investment cash[13] - Cash inflow from investment activities was ¥580.96 million, compared to ¥137.93 million in the prior year, indicating a strong recovery[31] - Cash outflow for investment activities increased to ¥537.25 million from ¥239.71 million, reflecting increased investment efforts[31] - The net cash flow from financing activities decreased to CNY -27,698,161.40, a 260.01% decline compared to CNY -7,693,688.13 in the previous year, primarily due to increased cash payments for debt repayment[13] - Net cash flow from financing activities was -$27.70 million, compared to -$7.69 million in the previous period, indicating a significant decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,487,572,269.44, a decrease of 0.93% from ¥9,576,915,691.47 at the end of the previous year[5] - Total current assets decreased to CNY 3,296,019,612.54 from CNY 3,781,514,679.73, a decline of about 12.8%[22] - Total liabilities decreased to CNY 1,293,326,789.33 from CNY 1,433,894,606.08, representing a reduction of approximately 9.8%[24] - Total equity attributable to shareholders increased to CNY 7,932,851,074.19 from CNY 7,879,949,193.44, showing a growth of about 0.67%[24] - Non-current assets totaled CNY 6,191,552,656.90, up from CNY 5,795,401,011.74, indicating an increase of about 6.8%[22] Shareholder Information - The company had a total of 146,867 common shareholders at the end of the reporting period[15] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[16] - The second-largest shareholder, Guangzhou Biomedical and Health Industry Investment Co., Ltd., owns 10.00% of the shares, totaling 140,344,607 shares[16] Operational Costs - Operating costs increased by 33.18% to ¥116,639,813.97, primarily due to increased amortization of long-term assets related to production[12] - Total operating costs increased to ¥238.18 million from ¥207.95 million, representing a growth of approximately 14.8% year-over-year[27] - Sales expenses rose significantly by 78.43% to ¥45,354,577.50, mainly due to reclassification of expense categories[12] Other Income and Fair Value - The company reported a significant increase in other income, reaching CNY 793,129.91, a 526.82% rise compared to CNY 126,532.41 in the previous period, mainly due to increased penalty income[13] - The company recorded a significant fair value gain of ¥200.73 million, contrasting with a loss of ¥365.57 million in the previous period, highlighting improved market conditions[27] Future Plans and Developments - The company has announced plans to obtain a medical device registration certificate, indicating ongoing efforts in product development[18] - The company plans to hold an online explanation meeting for the 2024 annual report, indicating a commitment to transparency and communication with stakeholders[20] - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[34] Miscellaneous - The first quarter report was not audited, which may affect the reliability of the financial data presented[33] - Current cash and cash equivalents amount to CNY 851,296,028.53, down from CNY 872,086,093.74 at the beginning of the period[21] - Accounts receivable decreased to CNY 1,171,534,622.86 from CNY 1,254,344,767.52, reflecting a reduction of approximately 6.6%[21] - Inventory increased to CNY 202,660,100.27 from CNY 198,214,544.62, reflecting a rise of approximately 2.3%[22] - Short-term borrowings decreased to CNY 117,637,389.36 from CNY 143,534,033.02, a decline of approximately 18%[23] - Cash and cash equivalents net increase was -$20.78 million, compared to a much larger decrease of -$199.21 million in the previous period[32] - The company reported a decrease in cash flow due to foreign exchange fluctuations, amounting to -$100,827.82[32]

广州达安基因股份有限公司（以下简称"公司"）监事会于近日收到监事会 主席朱琬瑜女士递交的书面辞职报告，朱琬瑜女士因工作原因申请辞去公司第八 届监事会主席及监事职务。朱琬瑜女士确认其与公司和公司监事会之间没有不同 意见，也没有任何有关其辞任监事会主席、监事须提呈公司股东注意的事宜。 根据《公司法》和《公司章程》的相关规定，朱琬瑜女士的辞职不会导致公 司监事会成员低于法定最低人数，上述辞职报告自送达监事会时生效。朱琬瑜女 士的离任不会对公司日常生产经营和管理产生影响。截止目前，朱琬瑜女士未持 有本公司股票。 朱琬瑜女士自担任本公司监事期间，忠实、勤勉地履行了各项职责，为公司 的经营发展作出了巨大贡献，公司经营管理层对朱琬瑜女士在职期间为公司所做 的贡献表示诚挚的感谢！ 特此公告。 广州达安基因股份有限公司 证券代码：002030 证券简称：达安基因 公告编号：2025-018 广州达安基因股份有限公司 关于监事会主席辞职的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 28 日 监 事 会 ...

Meeting Overview - The 2024 Annual General Meeting (AGM) of Guangzhou Da'an Gene Co., Ltd. was held on April 18, 2025, combining on-site and online voting methods [4][5] - A total of 593 shareholders and authorized representatives attended the meeting, representing 457,340,573 shares, which is 32.5870% of the total shares [6] Voting Results - The following proposals were approved during the meeting: - The 2024 Board of Directors Work Report received 99.2868% approval [8] - The 2024 Supervisory Board Work Report received 99.2783% approval [9] - The 2024 Financial Settlement Proposal received 99.2832% approval [10] - The 2024 Annual Report and its summary received 99.2876% approval [11] - The 2024 Profit Distribution Proposal received 99.2409% approval, with 74.1529% approval from minority investors [12] - The proposal for expected related party transactions for 2025 received 76.2190% approval [13] - The proposal for cash management using idle funds for 2025 received 99.2478% approval, with 74.3882% approval from minority investors [14] - The proposal regarding the termination of stock listing for a subsidiary received 99.3168% approval [15] Independent Directors' Report - Independent directors provided a detailed report on their activities during 2024, including attendance at board meetings and efforts to protect minority investors' rights [16] Legal Opinion - The meeting was witnessed by lawyers from Beijing Kangda (Guangzhou) Law Firm, who confirmed that the meeting's procedures and resolutions complied with relevant laws and regulations [17][18] Documentation - The resolutions from the AGM and the legal opinion from the law firm are available for review [19]

证券代码：002030 证券简称：达安基因 公告编号：2025-017 广州达安基因股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 4 月 18 日下午 14：30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 18 日上午 9：15-9：25，9：30-11：30 和下午 13：00-15：00；通 过深圳证券交易所互联网投票系统投票的时间为 2025 年 4 月 18 日上午 9:15 至 2025 年 4 月 18 日下午 15：00 期间的任意时间。 2、会议召开地点：广州市高新技术开发区科学城香山路 19 号公司一楼讲学 厅 5、会议主持人：公司董事长薛哲强先生 6、会议召开的合法、合规性：本次股东会的召开符合《公司法》 ...

北京市康达（广州）律师事务所 关于广州达安基因股份有限公司 2024 年度股东会的法律意见书 康达股会字[2025]第 0008 号 致：广州达安基因股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受广州达安基因股份有 限公司（下称"达安基因"或"公司"）委托，指派律师出席公司 2024 年度股 东会。根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共 和国证券法》（下称"《证券法》"）、《上市公司股东会规则》（下称"《股 东会规则》"）等法律、法规、规范性文件以及《广州达安基因股份有限公司章 程》（下称"达安基因《公司章程》"）的规定，本所律师对本次股东会的召集、 召开程序、召集人和出席会议人员资格以及表决方式、表决程序、表决结果等事 项进行见证并出具本法律意见书。 为出具本法律意见书，本所律师对达安基因本次股东会所涉事宜进行了审查， 查阅了相关会议文件，并对有关事项进行了必要的核查和验证。本所律师同意将 本法律意见书作为达安基因本次股东会公告材料，随同其他会议文件一并公告， 并依法对本法律意见书承担相应的责任。 本所律师根据相关法律、法规、规范性文件的要求，按照律师行业公认的业 ...

Core Viewpoint - After three years of high growth, the domestic IVD leader, Da An Gene, has experienced a significant decline in performance, with a projected revenue of approximately 853 million yuan in 2024, a year-on-year decrease of 27.27%, and a net loss of about 925 million yuan, marking the first negative net profit in nearly 20 years [2][3]. Financial Performance - In 2024, Da An Gene's revenue is expected to fall below 1 billion yuan, with total operating costs around 1.058 billion yuan, resulting in a total profit of approximately -1.071 billion yuan and a net loss of about 925 million yuan [3][4]. - The company reported a revenue of 12.046 billion yuan in 2022, with a net profit of approximately 5.412 billion yuan, and a non-recurring net profit of about 5.176 billion yuan [3][4]. - In 2023, the company saw a revenue decline of 90.2% and a net profit drop of 98.07%, with a non-recurring net profit decrease exceeding 100% [3]. Business Segments - Da An Gene's main business includes biological products and financial services, with biological product revenue in 2024 expected to decline by 28.57% to approximately 821 million yuan, accounting for 96.2% of total revenue [4]. - The sales of biological products, which include goods and services, saw a revenue drop of 32.06% to about 712 million yuan, while service revenue increased by 7.03% to approximately 99.15 million yuan [4]. Market Demand and Pricing - The decline in performance is attributed to reduced market demand and price adjustments, with significant price reductions for IVD products following several rounds of centralized procurement [5][6]. - The average price drop for 39 IVD products was reported at a median of 76.85%, with some products experiencing price cuts exceeding 90% [6]. Research and Development - Da An Gene has been continuously investing in research and development despite the decline in performance, although R&D expenses have decreased significantly due to staff reductions [8][9]. - R&D expenses fell by 56.96% in 2023 and by 25.36% in 2024, with a total of 3.02 billion yuan and 2.26 billion yuan respectively [8][9]. Workforce Changes - The company has seen a significant reduction in workforce, with total employees decreasing from 3,580 in 2022 to 1,730 in 2024, including a reduction of 979 technical staff [8][9]. - Management salaries have also decreased significantly, with the CEO's compensation dropping from 5.9672 million yuan in 2022 to 675,000 yuan in 2024 [8]. Future Outlook - Da An Gene has not provided specific timelines for market demand recovery but continues to focus on enhancing operational efficiency and product development across various diagnostic technology platforms [10].